Journal of Oncology / 2014 / Article / Tab 3

Review Article

The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis

Table 3

Patient characteristics of included zoledronic acid trials.

CharacteristicImmediate groupDelayed group
Z FASTZO FASTE-ZO FASTZ FASTZO FASTE-ZO FAST

Age, years
 Median
60
57
58
60
58
58
 Range35–8336–8740–8141–8937–8144–78
Race
 White
280

226
269
242
 Asian
89
21
93
19
 Black
9
14
 Caucasian
416
409
 Other
1227
518319
Baseline score
score > −1
217370163216367180
score ≤ −1 to ≥ −2
84162898516690
Postmenopausal status
 Postmenopausal
281
445
210
284
443
228
 Recently postmenopausal87429042
Bone mineral density
 Lumbar spine
  Mean1.1101.081.1061.08
  SD0.16520.160.16630.16
  Median1.0881.071.0821.06
  Range0.818–1.6490.79–1.670.807–1.6920.71–1.77
 Total hip
  Mean0.9580.960.9550.96
  SD0.12590.130.13220.13
  Median0.9540.940.9430.94
  Range0.676–1.3100.62–1.430.700–1.4750.62–1.55